Shawn Davis, PharmD: Glycopyrronium tosylate is an exciting therapy that will enable patients to have something topical. This is something that I believe is going to help patients. It is really going to have an impact on their lives and change the way that they live their lives.
Glycopyrronium tosylate is a medication that is actually going to meet the needs of patients in a way that they don’t have today. There aren’t good therapies on the market for patients to treat their hyperhidrosis and the condition that they have.
The next part is going to really be seeing what managed care’s outlook will be in paying for these medications. We are going to have a therapy. Just like with all therapies that are on the market, how do we pay for it? What’s going to be the mechanism by which payers and patients split the cost?
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link
November 21st 2024A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More